🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. TQB3616 capsules

    Chia Tai Tianqing Pharmaceutical Group Co.,

    HR-positive, HER2-negative Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  2. TRIPTORELIN, GONAPEPTYL 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée en seringues pré-remplies., LEUPRORELIN ACETATE, BAY 1841788, TRIPTORELIN, DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, DEGARELIX, LEUPRORELIN ACETATE

    The George Institute

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  3. TTI-101

    Tvardi Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  4. TTP889

    vTv Therapeutics

    Venous Thromboembolism

    phase 2 small molecule completed

    1 trial

  5. Tabelecleucel

    Evidence Based Cataract Study Group

    Nasopharyngeal Carcinoma

    phase 2 mab terminated

    1 trial

  6. Target-controlled naloxone-infusion

    BRIGHT MINDS BIOSCIENCES INC.

    Central Nervous System Sensitization

    phase 2 small molecule completed

    1 trial

  7. Tecentriq 1 200 mg concentrate for solution for infusion

    Tour Hekla

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  8. Tecentriq 1 200 mg concentrate for solution for infusion, OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion., CAPECITABINE VIATRIS 500 mg, comprimé pelliculé

    CERO THERAPEUTICS HOLDINGS, INC.

    microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis

    phase 2 small molecule active

    1 trial

  9. Tecentriq 1 200 mg concentrate for solution for infusion, Pulmocis 2 mg trousse pour préparation radiopharmaceutique, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Non resectable Hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  10. Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Disc Medicine

    Squamous cell carcinoma of the anal canal

    phase 2 small molecule active

    1 trial

  11. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene

    phase 2 small molecule active

    1 trial

  12. The corresponding placebo solution consists of the 25 nM phosphate buffer solution with 4 μg of vitamin B2 added for colouring purposes only., RBD1016, Vemlidy 25 mg film-coated tablets.

    Lacuna Pharma Pty Ltd

    Chronic hepatitis D virus infection

    phase 2 small molecule active

    1 trial

  13. The placebo is the same as the ensifentrine suspension except that the active ensifentrine ingredient is omitted (i.e., it consists of phosphate buffered saline and surfactants only); it is also supplied as a single unit-dose LDPE translucent ampule overwrapped in a foil pouch, Ensifentrine inhalation suspension

    Lacuna Pharma Pty Ltd

    Non-Cystic Fibrosis Bronchiectasis

    phase 2 small molecule active

    1 trial

  14. The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP., BRENSOCATIB, BRENSOCATIB

    Insmed Limited

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  15. The placebo will consist solely of the excipients of eblasakimab, i.e., the same formulation without the active ingredient and will be identical in appearance to eblasakimab. Pharmaceutical form: Solution for SC injection

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  16. The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  17. Theory-based counseling program

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 other completed

    1 trial

  18. Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Squamous cell carcinoma of the head and neck (SCCHN)

    phase 2 small molecule active

    1 trial

  19. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, RO7247669

    Hoffmann-La Roche

    Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  20. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  21. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  22. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  23. Tocilizumab

    Hospital Authority, Hong Kong

    Adamantinomatous Craniopharyngioma

    phase 2 small molecule active

    1 trial

  24. Tolinapant, Tolinapant

    Taiho Pharma Netherlands B.V.

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources